The chronic effects of hydroxy gas on people with Parkinson’s disease - a case study

Not Applicable

• Conditions: Parkinson's disease; Nervous System Diseases

• Registration Number: ISRCTN46799043
• Lead Sponsor: niversity of Kent

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-05
• Last Update Posted: 4 December 2023
• Study Completion: 2024-03-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

1. All participants must have a diagnosis of PD by a Neurologist or Geriatrician.
2. All participants must be at stage 2 or stage 3 on the Hoehn and Yahr (H&Y) scale. Stage 1 is too mild and stages 4 and 5 could potentially be too severe for appropriate study participation.
3. Male or female.
4. Able to attend the School of Sport and Exercise Sciences facilities
5. Able to inhale gas for 30 min, twice daily, for a period of 8 weeks
6. Participants' disease state must be stable over the past 2 months

Exclusion Criteria

1. Participants whose Parkinson’s is not controlled.
2. Participants who are at stage 1, stage 4 and stage 5 of the H&Y scale.
3. Participants who cannot consent for themselves.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function and manual dexterity to be measured using a Purdue Pegboard Test (the three-trial administration test-retest will be used to increase reliability) at each visit (at baseline, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation.

Secondary Outcome Measures

Name	Time	Method
<br> Measures 1-4 will be assessed at time points of: baseline, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation, after 2 weeks of placebo gas inhalation, after 2 weeks of hydroxy gas inhalation.<br> 1.Transient mood measured using a Profile of Mood States (POMS)– Short Form.<br> 2. Visual attention measured using The Flanker Compatibility Task<br> 3. The burden of non-motor symptoms, including non-motor fluctuations, using the Movement Disorder Society Non-Motor Rating Scale<br> 4. Blood markers of oxidative stress, inflammation/neuro inflammation, BDNF will measured in serum or plasma derived from venous blood samples<br> 5. Levels of physical activity measured by an activity tracker worn continuously for eight weeks<br>